Journal
CURRENT OPINION IN HIV AND AIDS
Volume 4, Issue 3, Pages 194-199Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/COH.0b013e328329fc8d
Keywords
calendar time; cohort; combination antiretroviral therapy; outcome; randomized controlled trail
Categories
Funding
- Gilead
- GlaxoSmithKline
- Bristol Myers Squibb
- Boehringer-Ingelheim
- Abbott
Ask authors/readers for more resources
Purpose of review The introduction of combination antiretroviral therapy (cART) led to substantial reductions in HIV-associated morbidity and mortality. However, the regimens in the early cART era were cumbersome and toxic. The introduction of new ART agents, fixed-dose combinations and novel strategies for cART delivery such as ritonavir 'boosting' of HIV-protease inhibitors have led to a perception of improvements in the tolerability and durability of contemporary cART regimens. It is in turn assumed that these developments have led to improved outcomes in the latter era of cART. Recent findings Both cohort studies and randomized clinical trials suggest improvements in cART outcomes over calendar time. Key associated factors include reduced pill burden and dosing interval and improved tolerability and reduced toxicity of newer ART. A critical appreciation of the association between ART adherence and regimen durability has been important. Cohorts in recent times have included more patients who are completely ART-naive at therapy initiation. Summary The prognosis of HIV infection in developed countries is in the order of 40 years after cART initiation. An appreciation of the factors associated with long-term control of HIV viraemia is essential for the optimal management of the HIV-infected individual in contemporary practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available